Ole Johan Halvorsen

Emeritus

Department of Clinical Medicine

E-mailole.halvorsen@uib.no
Visitor Address
Avdeling for patologi, Haukeland Universitetssykehus

Bergen
Postal Address
Postboks 7804

5020 Bergen

Publications

Academic article

Show author(s) (2023). Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer. Scientific Reports.
Show author(s) (2023). A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. Cancer Immunology and Immunotherapy.

Show author(s) (2022). PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression. Nature Communications. 1-19.
Show author(s) (2022). MicroRNAs in Differentiation of Embryoid Bodies and the Teratoma Subtype of Testicular Cancer. Cancer Genomics & Proteomics. 178-193.

Show author(s) (2021). The epithelial–mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients. The journal of pathology. Clinical research. 253-270.
Show author(s) (2021). Preoperative predictors of pathological tumour stage and prognosis may be used when selecting candidates for intensified treatment in upper tract urothelial carcinoma. Scandinavian Journal of Urology. 100-107.
Show author(s) (2021). Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study. World Journal of Urology. 1-7.

Show author(s) (2020). Ten-year results from a phase II study on image guided, Intensity Modulated Radiation Therapy with simultaneous integrated boost in high-risk prostate cancer. Advances in Radiation Oncology. 396-403.
Show author(s) (2020). Magnetic resonance radiomics for prediction of extraprostatic extension in non-favorable intermediate- and high-risk prostate cancer patients. Acta Radiologica. 1570-1579.
Show author(s) (2020). Assessing extraprostatic extension by mpMRI of the prostate: Mehralivand’s EPE grade or EPE Likert score? Radiology: Imaging Cancer. 1-10.

Show author(s) (2019). Tumour architecture, grade and location remain predictors of non-organ-confined upper tract urothelial carcinoma at time of radical nephroureterectomy: results from a multicenter Norwegian external validation study. World Journal of Urology. 717-723.
Show author(s) (2019). FOXC2 expression and epithelial–mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer. The journal of pathology. Clinical research. 272-286.

Show author(s) (2018). Novel protein signatures suggest progression to muscular invasiveness in bladder cancer. PLOS ONE. 1-15.
Show author(s) (2018). Intensity-based volumetric registration of magnetic resonance images and whole-mount sections of the prostate. Computerized Medical Imaging and Graphics. 24-30.
Show author(s) (2018). Dictionary-based through-plane interpolation of prostate cancer T2-weighted MR images. Signal Processing - Algorithms, Architectures, Arrangements, and Applications Conference Proceedings, SPA. 168-173.
Show author(s) (2018). CRF-Based clustering of pharmacokinetic curves from dynamic contrast-enhanced MR images. Signal Processing - Algorithms, Architectures, Arrangements, and Applications Conference Proceedings, SPA. 174-179.

Show author(s) (2017). Rule-based data-driven approach for computer aided diagnosis of the peripheral zone prostate cancer from multiparametric MRI: Proof of concept. Signal Processing - Algorithms, Architectures, Arrangements, and Applications Conference Proceedings, SPA. 90-95.
Show author(s) (2017). Reconstruction of high-resolution T2W MR images of the prostate using maximum a posteriori approach and Markov random field regularization. Signal Processing - Algorithms, Architectures, Arrangements, and Applications Conference Proceedings, SPA. 96-99.
Show author(s) (2017). Optimising preoperative risk stratification tools for prostate cancer using mpMRI. European Radiology. 1016-1026.

Show author(s) (2016). Grading of urothelial carcinoma of the upper urinary tract according to the World Health Organization/International Society of Urological Pathology classification from 2004 is a valuable tool when considering whether a patient is suitable for endoscopic treatment. Scandinavian Journal of Urology. 298-304.
Show author(s) (2016). A positive Real-Time Elastography (RTE) combined with a Prostate Cancer Gene 3 (PCA3) score above 35 convey a high probability of intermediate- or high-risk prostate cancer in patient admitted for primary biopsy. BMC Urology. 1-8.

Show author(s) (2015). Prostate cancer antigen-3 (PCA3) and PCA3-based nomograms in the diagnosis of prostate cancer: an external validation of Hansen's nomogram on a Norwegian cohort. Scandinavian Journal of Urology. 8-15.
Show author(s) (2015). 1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy. Acta Radiologica. 500-511.

Show author(s) (2014). GRK3 is essential for metastatic cells and promotes prostate tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 1521-1526.
Show author(s) (2014). A positive real-time elastography is an independent marker for detection of high-risk prostate cancers in the primary biopsy setting. BJU International. E90-E97.

Show author(s) (2013). Bone marrow-derived Gr1(+) cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discovery. 578-589.

Show author(s) (2012). Combination of real-time elastography and urine prostate cancer gene 3 (PCA3) detects more than 97 % of significant prostate cancers. Scandinavian Journal of Urology and Nephrology. 211-216.

Show author(s) (2010). Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980-2007. Cancer Detection and Prevention. 359-367.

Show author(s) (2009). TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS - Journal of Pathologiy, Microbiology and Immunology. 575-582.
Show author(s) (2009). Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proceedings of the National Academy of Sciences of the United States of America. 12115-12120.
Show author(s) (2009). Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Research. 4708-4715.
Show author(s) (2009). Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy. Acta Oncologica. 874-881.
Show author(s) (2009). Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLOS ONE. 14 pages.
Show author(s) (2009). Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU International. 1647-1654.

Show author(s) (2008). WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clinical Cancer Research. 1397-1406.

Show author(s) (2007). Increased expression of sim2-s protein is a novel marker of aggressive prostate cancer. Clinical Cancer Research. 892-897.
Show author(s) (2007). ERG upregulation and related ETS transcription factors in prostate cancer. International Journal of Oncology. 19-32.
Show author(s) (2007). Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
Show author(s) (2007). A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer. Clinical Cancer Research. 7003-7011.

Show author(s) (2006). Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. Acta Oncologica. 454-462.
Show author(s) (2006). Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical 14 retropubic prostatectomy for localized prostate cancer? BJU International. 51-55.
Show author(s) (2006). Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Archiv. 68-74.
Show author(s) (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology. 268-273.
Show author(s) (2006). A concomitant tumour boost in bladder irradiation: Patient suitability and the potential of intensity-modulated radiotherapy. Radiotherapy and Oncology. 98-105.

Show author(s) (2005). Gene expression profiles in prostate cancer: Association with patient subgroups and tumour differentiation. International Journal of Oncology. 329-336.

Show author(s) (2003). Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clinical Cancer Research. 1474-1479.
Show author(s) (2003). Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded: a prospective study of 510 patients. Urology. 447-450.

Show author(s) (2002). Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Research. 6808-6811.

Show author(s) (2001). Neonatal lethal dwarfism with distinct skeletal malformations - separate entity? Pediatric Radiology. 663-668.
Show author(s) (2001). Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Research. 7 pages.

Show author(s) (2000). Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer. 416-24.
Show author(s) (2000). Independent prognostic importance of microvessel density in clinical localized prostate cancer. Anticancer Research. 3791-800.

Show author(s) (1999). Use of pelvic surface coil MR imaging for assessment of clinically localised prostate cancer with histopathologic correlation. Clinical Radiology. 164-69.
Show author(s) (1999). MRI with an endorectal coil for staging of clinically localised prostate cancer prior to radical prostatectomy. European Journal of Radiology. 29-34.

Show author(s) (1997). When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? British Journal of Urology. 770-776.
Show author(s) (1997). Tumour size measured by transrectal ultrasonography in the staging of prostate cancer before radical prostatectomy. British Journal of Urology. 269-273.
Show author(s) (1997). Transcutaneous abdominal ultrasonography in the staging of lung cancer. Thorax. 276-280.
Show author(s) (1997). Lymphangiography combined with biopsi and computer tomography to detect lymph node metastases in localized prostate cancer. Scandinavian Journal of Urology and Nephrology. 116-119.
Show author(s) (1997). Expression of p16 protein in prostatic adenocarcinomas, intraepithelial neoplasia and benign/hyperplastic glands. Urologic Oncology. 59-66.

Show author(s) (1989). Enzyme activities in the duodenal mucosa in duodenal ulcer patients. Scandinavian Journal of Gastroenterology. 244-250.
Show author(s) (1989). Enzyme Activities in the Gastric and Duodenal Mucosa in Duodenal Ulcer. Scandinavian Journal of Gastroenterology, Supplement. 44.
Show author(s) (1989). Enzyme Activities in the Duodenal Mucosa in Duodenal Ulcer Patients. Scandinavian Journal of Gastroenterology. 244-250.

Popular scientific lecture

Show author(s) (2005). Overexpression of ERG and SIM2 transcription factors in prostate cancer.

Academic lecture

Show author(s) (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC) .

Show author(s) (2012). Radikale prostatektomier ved Haukeland universitetssjukehus 2010-2012.
Show author(s) (2012). Læringskurven for RALP ved Haukeland universitetssjukehus 2010-2012.
Show author(s) (2012). Lymfekjerteltoilette (PLND) ved radikale prostatektomier ved Haukeland universitetssjukehus 2010-2012.

Show author(s) (2010). Real time elastografi ved cancer prostatae.
Show author(s) (2010). Preliminære resultater av PCA3 måling i urin hos pasienter med cancer prostatae.
Show author(s) (2010). Er preoperativ MR-prostata nyttig for å avklare korrekt T-stadium forut for kirurgi?
Show author(s) (2010). Er MR-prostata nyttig for å avklare videre oppfølgningsbehov hos pasienter med 2 eller flere negative biopsiserier?

Show author(s) (2009). Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
Show author(s) (2009). Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.

Show author(s) (2008). Polycomb group target genes and bivalent H3K4 & K27me3 modifications in human embryonic cells were enriched among dysregulated genes in prostate cancer.
Show author(s) (2008). Epithelial to mesenchymal transition of a primary, immortalized prostate cell line is associated with gene expression switches of entire cell attachment modules.

Show author(s) (2007). Functional oncogenomics and epigenomics analysis of prostate cancer.
Show author(s) (2007). Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients and identification of ERG target genes.

Show author(s) (2006). Global gene expression analysis of transcription factors in prostate cancer and cell lines.
Show author(s) (2006). ERG upregulation and related transcription factors in prostate cancer.

Show author(s) (2004). Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.
Show author(s) (2004). Gene expression profiles in prostate cancer: identification of upregulated SIM2 gene validated in archival tissue, relation to histological grading and prognosis.
Show author(s) (2004). Dose response in a series of 495 patients with early prostate cancer.

Show author(s) (2003). Global analysis of gene expression and regulatory patterns in urogenital tumours using DNA microarrays.
Show author(s) (2003). Gene expression profiling in prostate cancer: Cluster analysis and association with tumor differentiation.
Show author(s) (2003). Gene expression profiling in prostate cancer.
Show author(s) (2003). DNA microarray studies of human cancer - pitfalls and outlook.
Show author(s) (2003). Comparison of DNA microarray and real time quantitative PCR for quantitation of gene expression of selected genes in prostate cancer.

Show author(s) (2001). Prognostisk betydning av angiogenese (microvessel density - MVD) og proliferasjonsmarkøren Ki-67 ved lokalisert prostatacencer.
Show author(s) (2001). Neonatal lethal dwarfism with distinct skeletal malformations - a separate entity?

Show author(s) (2000). Independent prognostic importance of the proliferation marker KI-67 in clinically localized prostate cancer.

Show author(s) (1989). Enzyme Activities in the Gastric and Duodenal Mucosa in Duodenal Ulcer Patients.

Short communication

Show author(s) (2023). A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC. Journal of Clinical Oncology.

Doctoral dissertation

Show author(s) (2007). Molecular and prognostic markers in prostate cancer. A study of cell-cycle regulators, angiogenesis and candidate markers.

Abstract

Show author(s) (2009). Proliferation of immature tumor vessels is a novel marker of clinical progress in prostate cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 233-233.

Show author(s) (2008). Vascular proliferation by Nestin/Ki-67 is a novel predictor of the clinical progress of prostate cancer. Histopathology. 276-277.

Show author(s) (2007). Epithelial to mesenchymal transition is of strong prognostic importance in prostate cancer. Virchows Archiv. 344-344.

Show author(s) (2006). Global gene expression analysis of transcription factors in prostate cancer and cell lines. International Journal of Molecular Medicine. S27.
Show author(s) (2006). ERG upregulation in relation to other transcription factors in prostate cancer. NBS-nytt. 72.

Show author(s) (2005). Single-minded 2 homolog gene is overexpressed in prostate cancer. Virchows Archiv. 432-432.
Show author(s) (2005). Overexpression of ERG and SIM2 transcription factors in prostate cancer. International Journal of Molecular Medicine. S76-S76.

Poster

Show author(s) (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC).

Show author(s) (2014). Registration of multiparametric MRI and whole-mount sections of the prostate.
Show author(s) (2014). Registration of multiparametric MRI and whole-Mount sections prostate.

Show author(s) (2009). Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
Show author(s) (2009). Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
Show author(s) (2009). Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
Show author(s) (2009). Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.

Show author(s) (2008). Polycomb (PcG) targets are enriched in repressed genes in prostate cancer.

Show author(s) (2007). Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients.

Show author(s) (2006). Single-minded 2 homolog (SIM2) is overexpressed in prostate cancer.
Show author(s) (2006). ERG upregulation in relation to other transcription factors in prostate cancer.

Show author(s) (2005). Very high expression of specific transcription factors in prostate cancer compared with paired benign prostate tissue.
Show author(s) (2005). Single-minded 2 homolog gene (SIM2) is overexpressed in prostate cancer.
Show author(s) (2005). ETS transcription factors in prostate cancer.

Show author(s) (2003). Preoperative PSA may not be a predictor of clinical recurrence after radical prostatectomy.
Show author(s) (2003). Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.

Show author(s) (2002). Expression of PTEN/P27 proteins in prostate cancer using a tissue microarray setup predicts progression after radical prostatectomy.

Academic literature review

Show author(s) (2008). Molecular and prognostic markers in prostate cancer - A study of cell-cycle regulators, angiogenesis and candidate markers - Introduction. APMIS - Journal of Pathologiy, Microbiology and Immunology. 8-62.

More information in national current research information system (CRIStin)